A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
Authors
Keywords
-
Journal
LEUKEMIA
Volume 25, Issue 2, Pages 341-347
Publisher
Springer Nature
Online
2010-12-07
DOI
10.1038/leu.2010.226
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia
- (2010) Irene M. Ghobrial et al. JOURNAL OF CLINICAL ONCOLOGY
- Dissecting the role of mTOR: Lessons from mTOR inhibitors
- (2009) Ryan J.O. Dowling et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
- (2009) M. Gupta et al. BLOOD
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
- (2009) Susan L. Ellard et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
- (2009) V Ramakrishnan et al. ONCOGENE
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
- (2008) C. H. Geisler et al. BLOOD
- Long‐term results of the treatment of patients with mantle cell lymphoma with cladribine (2‐CDA) alone (95‐80‐53) or 2‐CDA and rituximab (N0189) in the North Central Cancer Treatment Group
- (2008) David J. Inwards et al. CANCER
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
- Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
- (2008) J LOPICCOLO et al. DRUG RESISTANCE UPDATES
- Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning
- (2008) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
- Population-Based Analysis of Incidence and Outcome of Transformed Non-Hodgkin's Lymphoma
- (2008) Abdulwahab J. Al-Tourah et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started